Nested Therapeutics

Focus: Nested Therapeutics is a public biotech company focused on non-degrading molecular glue therapeutics, a novel platform targeting oncology and potentially other disease areas. The company operates at an early stage with a single Phase 1 program in clinical development.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Total Funding

$125M

Open Jobs

About Nested Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Nested Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NST-628

Oncology

PHASE_1

Clinical Trials (1)

NCT06326411A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Phase 1

Help build intelligence for Nested Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on a novel, differentiated platform (non-degrading molecular glue) with potential to address large oncology markets
Public company status provides equity liquidity and institutional resources rare at this early stage
Early-stage pipeline means significant upside potential if NST-628 advances and validates the platform

Watch Out For

Only 1 clinical trial across the entire company pipeline signals extremely early stage with unproven science and high technical risk
No approved products, no revenue, and missing financial data (funding, cash position unknown) create significant uncertainty around runway and sustainability
Zero current job openings and sparse publication output (3 total) suggest limited scale and slow hiring momentum

Generated by Claude from Nested Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Oncology

Publications: 3 in PubMed

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline

Research Publications(3)

Recent peer-reviewed publications with author affiliations at this company

Machine Learning ADME Models in Practice: Four Guidelines from a Successful Lead Optimization Case Study.

ACS medicinal chemistry letters

2024

PMID:39140048

The Pan-RAF-MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS-MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers.

Cancer discovery

2024

PMID:38588399